Eight patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2040. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2040
Next term end
6
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2043.202620302034203820422043
13 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Aug 2040 · High confidence
Also notable
Ends Mar 2043 · High confidence
Antibodies Against ILT2
US 11,236,162
Granted 2022. Computed term ends 2040.
Methods of Identifying Agents That Block MCD28 Cleavage by MMPS
US 12,612,459
A family of 6 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- Oct 8Assignment recorded on 1 record: Fridman-Dror, Anna and 8 others to Biond Biologics Ltd. Recorded Oct 8, 2026, executed Sep 23, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76306, frame 51.
- Sep 29Assignment recorded on 1 record: Peretz, Tsuri and 7 others to Biond Biologics Ltd. Recorded Sep 29, 2026, executed Feb 25, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76599, frame 359.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Small Shedding Blocking Agents | 2 in force | to Mar 2043 |
| Antibodies Against ILT2 | 2 in force | to Aug 2040 |
| Shedding Blocking Agents with Increased Stability | 1 in force | to Apr 2043 |
| Intracellular Delivery Compositions | 1 in force | to Apr 2042 |
| Methods and Compositions for Decreasing Soluble Immune Receptor CD28 | 1 in force | to Feb 2042 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,236,162 | Antibodies Against ILT2 In force · High confidence | In force | High confidence | |
| US 12,071,479 | Antibodies Against ILT2 and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,391,755 | Methods of Use for Anti- ILT2 Antibodies In force · High confidence | In force | High confidence | |
| US 12,139,534 | Methods and Compositions for Decreasing Soluble Immune Receptor CD28 In force · High confidence | In force | High confidence | |
| US 12,544,451 | Intracellular Delivery Compositions In force · High confidence | In force | High confidence | |
| US 12,612,459 | Methods of Identifying Agents That Block MCD28 Cleavage by MMPS In force · High confidence | In force | High confidence | |
| US 12,503,510 | Small Shedding Blocking Agents In force · High confidence | In force | High confidence | |
| US 12,589,163 | Shedding Blocking Agents with Increased Stability In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 13 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.